| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA134: Infliximab for the treatment of adults with psoriasis |
|
Medicine details |
|
| Medicine name | infliximab (Remicade®) |
| Formulation | powder for concentrate for solution for infusion |
| Reference number | 169 |
| Indication | Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen/ultraviolet A treatment (PUVA) |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/12/2006 |
| NICE guidance | TA134: Infliximab for the treatment of adults with psoriasis |